A first-in-class GPR183 antagonist was developed for the treatment of rheumatoid arthritis.
A first-in-class GPR183 antagonist was developed for the treatment of rheumatoid arthritis.
Cpyright © 2025 Nanjing Immunophage Biomedical Co.,Ltd
All Rights Reserved. 苏ICP备2022026466号-1 
苏公网安备 32011202000830号
Click here to learn more